Anxiety & Creativity (01:58:55) Convergent Interests & Romantic Relationships (02:07:19) Self-Awareness, Core Values & Romantic Relationships (02:15:27) Non-Verbal Communication & Relationships (02:24:58) Eyes, Voice, Intuition & Seduction (02:28:38) Virtual World, Social Skills, Non-Verbal Communication (02:32:19) Self-Awareness & Intelligence, Artificial Intelligence (AI), Nuance (02:41:43) Human Brain, Plasticity (02:45:18) Stroke & Near-Death Experiences, Self, Time (02:55:49) Appreciation & Near-Death Experience, Urgency (03:01:36) Death Ground & Urgency (03:09:13) Zero-Cost Support, Spotify & Apple Reviews, Sponsors, YouTube Feedback, Momentous, Social Media, Neural Network Newsletter Disclaimer Day 163 Dr
Inzucchi, MD, director of the Yale Medicine Diabetes Center and clinical director of the section of endocrinology and professor of medicine (endocrinology) at Yale School of Medicine, presented additional details on oral semaglutide and CV outcomes by baseline HbA1c in the SOUL trial
Key distinctions matter because they guide evaluation: a globus sensation without difficulty swallowing or breathing is usually benign, whereas actual trouble swallowing (dysphagia), pain when swallowing (odynophagia), or any breathing difficulty should prompt faster medical assessment
Our new meta-analysis in @EJPCEiC (~49,000 pts) shows a 17% reduction in new-onset AFib
Based on this evidence, and the results generated in the present study, once-weekly semaglutide would likely represent an effective treatment while providing value for money if used as second-line therapy in the general population with type 2 diabetes in the UK
